BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Praxis Precision Medicines\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Praxis Precision Medicines\, Inc.
 's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07010471-8983@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Relutrigine: Phase 3 readout est. (NCT07010471)
DESCRIPTION:Relutrigine\, phase 3\, Epilepsy.\nStudy: A Clinical Trial for 
 Participants With DEE to Assess Efficacy\, Safety\, Tolerability\, and PK 
 of Relutrigine\nEstimated primary completion: December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/relutrigine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07010471
URL:https://assetmemo.bio/drug/relutrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07019922-8868@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Elsunersen: Phase 3 readout est. (NCT07019922)
DESCRIPTION:Elsunersen\, phase 3\, Epilepsy.\nStudy: A Clinical Trial of El
 sunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/elsunersen#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07019922
URL:https://assetmemo.bio/drug/elsunersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505004-8949@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vormatrigine: Phase 3 readout est. (NCT07505004)
DESCRIPTION:Vormatrigine\, phase 3\, Epilepsy.\nStudy: Randomized Clinical 
 Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Fo
 cal Seizures\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/vormatrigine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07505004
URL:https://assetmemo.bio/drug/vormatrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287163-8949@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Vormatrigine: Phase 3 readout est. (NCT07287163)
DESCRIPTION:Vormatrigine\, phase 3\, Epilepsy.\nStudy: Clinical Trial of Vo
 rmatrigine in Adult Patients With Epilepsy\nEstimated primary completion: 
 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vormatri
 gine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07287163
URL:https://assetmemo.bio/drug/vormatrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
